Polycythemia Vera | Executive Insights | US | 2019
Polycythemia Vera (PV) is a rare hematological malignancy estimated to affect approximately 50 thousand patients in the United States. Based on patient’s age and prior clinical history patients can be classified into low- and high-risk PV; based on this classification, the treatment approach and patient’s prognosis are different. Pharmacologic treatment of PV patients includes hydroxyurea, interferons and ruxolitinib (Incyte’s Jakafi), and is considered adequate for a relatively large group of patients. However, there is not a curative therapy, and there is an unmet need for certain population segments. As such, there is a commercial opportunity for therapies that are able to differentiate form the current standard of care.
QUESTIONS ANSWERED
- What are the key areas of unmet need and opportunity in the PV market?What is the approximate size of the diagnosed PV population in the United States?
- What is the expected impact of novel therapy launches, especially drugs with novel mechanisms of action?How does each current and future player influence the market and how will this change in the future?
- What are the key drivers and limiters of the PV market?
CONTENT HIGHLIGHTS
- Geography: United States
- Primary Research: Three KOL interviews in May 2019
- Key Companies Covered: Incyte, Merck & Co., Roche/Genentech, Kartos Therapeutics, PharmaEssentia, ItalfarmacoKey
- Drugs Covered: Ruxolitinib, Jakafi, interferons, KRT-232, idasanutlin, ropeginterferon α-2b, givinostat
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
